Positive Outcomes of Denosumab Treatment in 2 Patients With Cherubism

Eitan Bar Droma, Guy Beck-Rosen, Anatoly Ilgiyaev, Yariv Fruchtman, Chen Abramovitch-Dahan, Noam Levaot, Navot Givol

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Cherubism is a rare autosomal dominant disease whose severity ranges widely, from asymptomatic to life-threatening. Bilateral symmetrical painless expansion of the mandible and maxilla resulting in a typical appearance of the face resembling a cherub, are the highlighted features of the condition. In most cases, cherubism-induced lesions in the jaws appear around the age of 3 years and tend to expand and increase in numbers until puberty. Treatment options for cherubism range from observation to surgical correction and various pharmacologic therapies. Given the excess sensitivity of cherubism osteoclasts to RANKL (receptor activator of nuclear factor κB ligand) and the positive effects of denosumab (XGEVA; Amgen, Thousand Oaks, CA) treatment in patients with giant cell granuloma, we have designed a treatment based on denosumab for 2 cherubism patients that achieves what we consider promising results.

Original languageEnglish
Pages (from-to)2226-2234
Number of pages9
JournalJournal of Oral and Maxillofacial Surgery
Issue number12
StatePublished - 1 Dec 2020

ASJC Scopus subject areas

  • Surgery
  • Oral Surgery
  • Otorhinolaryngology


Dive into the research topics of 'Positive Outcomes of Denosumab Treatment in 2 Patients With Cherubism'. Together they form a unique fingerprint.

Cite this